Overview Dividends

(WST) West Pharmaceutical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9553061055

Stoppers, Seals, Syringes, Cartridges, Self-Injection Devices

WST EPS (Earnings per Share)

EPS Growth (3Y CAGR): 3.78%
EPS Trend (3Y Correlation): -30.4%

WST Revenue

Revenue Growth (3Y CAGR): 4.73%
Revenue Trend (3Y Correlation): 44.3%

Description: WST West Pharmaceutical October 16, 2025

West Pharmaceutical Services (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The company operates two segments: Proprietary Products, which provides stoppers, seals, syringe and cartridge components, advanced reconstitution and mixing technologies, and integrated services such as analytical labs and regulatory support; and Contract-Manufactured Products, which delivers automated assembly of devices for surgical, diagnostic, ophthalmic, injectable, and consumer-health applications.

Key recent metrics show FY 2023 revenue of approximately $2.5 billion, an operating margin near 13 %, and earnings per share of $5.30, with a modest dividend yield of about 1.2 %. Growth is being driven by the expanding biologics market-projected to outpace small-molecule drugs at a CAGR of ~8 % through 2028-and heightened demand for sterile, high-integrity packaging amid tighter regulatory scrutiny on drug safety.

If you want a deeper, data-rich view of West’s valuation and competitive positioning, a quick look at ValueRay’s analyst toolkit can help you surface the most material assumptions and scenario analyses.

WST Stock Overview

Market Cap in USD	20,643m
Sub-Industry	Health Care Supplies
IPO / Inception	1978-01-13

WST Stock Ratings

Growth Rating	-13.5%
Fundamental	71.6%
Dividend Rating	52.7%
Return 12m vs S&P 500	-27.0%
Analyst Rating	4.69 of 5

WST Dividends

Dividend Yield 12m	0.38%
Yield on Cost 5y	0.37%
Annual Growth 5y	5.66%
Payout Consistency	96.5%
Payout Ratio	12.0%

WST Growth Ratios

Growth Correlation 3m	94.4%
Growth Correlation 12m	-27%
Growth Correlation 5y	-33%
CAGR 5y	4.58%
CAGR/Max DD 3y (Calmar Ratio)	0.09
CAGR/Mean DD 3y (Pain Ratio)	0.23
Sharpe Ratio 12m	-0.43
Alpha	-33.78
Beta	1.165
Volatility	37.33%
Current Volume	1038.4k
Average Volume 20d	685.1k
Stop Loss	265.2 (-3.7%)
Signal	1.43

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (491.7m TTM) > 0 and > 6% of Revenue (6% = 181.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 39.37% (prev 35.95%; Δ 3.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 693.8m > Net Income 491.7m (YES >=105%, WARN >=100%)

Net Debt (-325.5m) to EBITDA (770.0m) ratio: -0.42 <= 3.0 (WARN <= 3.5)

Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (72.7m) change vs 12m ago -0.95% (target <= -2.0% for YES)

Gross Margin 35.59% (prev 35.00%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 77.55% (prev 78.26%; Δ -0.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 432.1 (EBITDA TTM 770.0m / Interest Expense TTM 1.40m) >= 6 (WARN >= 3)

Altman Z'' 10.49

(A) 0.29 = (Total Current Assets 1.82b - Total Current Liabilities 635.4m) / Total Assets 4.11b

(B) 1.04 = Retained Earnings (Balance) 4.26b / Total Assets 4.11b

warn (B) unusual magnitude: 1.04 — check mapping/units

(D) 3.96 = Book Value of Equity 4.18b / Total Liabilities 1.05b

Total Rating: 10.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.62

1. Piotroski 6.50pt = 1.50

2. FCF Yield 1.87% = 0.93

3. FCF Margin 12.56% = 3.14

4. Debt/Equity 0.10 = 2.50

5. Debt/Ebitda -0.42 = 2.50

6. ROIC - WACC (= 6.24)% = 7.80

7. RoE 17.33% = 1.44

8. Rev. Trend 44.26% = 3.32

9. EPS Trend -30.36% = -1.52

What is the price of WST shares?

As of November 07, 2025, the stock is trading at USD 275.34 with a total of 1,038,400 shares traded.
Over the past week, the price has changed by -1.15%, over one month by +2.71%, over three months by +16.04% and over the past year by -16.15%.

Is West Pharmaceutical a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, West Pharmaceutical (NYSE:WST) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 71.62 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WST is around 258.74 USD . This means that WST is currently overvalued and has a potential downside of -6.03%.

Is WST a buy, sell or hold?

West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.

Strong Buy: 10
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the WST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	350.8	27.4%
Analysts Target Price	350.8	27.4%
ValueRay Target Price	292.8	6.3%

WST Fundamental Data Overview November 06, 2025

Market Cap USD = 20.64b (20.64b USD * 1.0 USD.USD)
P/E Trailing = 41.4653
P/E Forward = 37.037
P/S = 6.8403
P/B = 6.7059
P/EG = 3.4316
Beta = 1.165
Revenue TTM = 3.02b USD
EBIT TTM = 604.9m USD
EBITDA TTM = 770.0m USD
Long Term Debt = 202.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 22.9m USD (from shortTermDebt, last quarter)
Debt = 303.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -325.5m USD (from netDebt column, last quarter)
Enterprise Value = 20.32b USD (20.64b + Debt 303.0m - CCE 628.5m)
Interest Coverage Ratio = 432.1 (Ebit TTM 604.9m / Interest Expense TTM 1.40m)
FCF Yield = 1.87% (FCF TTM 379.1m / Enterprise Value 20.32b)
FCF Margin = 12.56% (FCF TTM 379.1m / Revenue TTM 3.02b)
Net Margin = 16.30% (Net Income TTM 491.7m / Revenue TTM 3.02b)
Gross Margin = 35.59% ((Revenue TTM 3.02b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 36.49% (prev 35.66%)
Tobins Q-Ratio = 4.95 (Enterprise Value 20.32b / Total Assets 4.11b)
Interest Expense / Debt = 0.03% (Interest Expense 100.0k / Debt 303.0m)
Taxrate = 19.54% (34.0m / 174.0m)
NOPAT = 486.7m (EBIT 604.9m * (1 - 19.54%))
Current Ratio = 2.87 (Total Current Assets 1.82b / Total Current Liabilities 635.4m)
Debt / Equity = 0.10 (Debt 303.0m / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = -0.42 (Net Debt -325.5m / EBITDA 770.0m)
Debt / FCF = -0.86 (Net Debt -325.5m / FCF TTM 379.1m)
Total Stockholder Equity = 2.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.98% (Net Income 491.7m / Total Assets 4.11b)
RoE = 17.33% (Net Income TTM 491.7m / Total Stockholder Equity 2.84b)
RoCE = 19.90% (EBIT 604.9m / Capital Employed (Equity 2.84b + L.T.Debt 202.6m))
RoIC = 16.40% (NOPAT 486.7m / Invested Capital 2.97b)
WACC = 10.16% (E(20.64b)/V(20.95b) * Re(10.31%) + D(303.0m)/V(20.95b) * Rd(0.03%) * (1-Tc(0.20)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 69.78% ; FCFE base≈356.1m ; Y1≈343.9m ; Y5≈340.2m
Fair Price DCF = 58.46 (DCF Value 4.21b / Shares Outstanding 71.9m; 5y FCF grow -4.67% → 3.0% )
EPS Correlation: -30.36 | EPS CAGR: 3.78% | SUE: 1.45 | # QB: 3
Revenue Correlation: 44.26 | Revenue CAGR: 4.73% | SUE: 0.72 | # QB: 0

Additional Sources for WST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle